Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.
| Revenue (TTM) | $36.36B |
| Gross Profit (TTM) | $23.75B |
| EBITDA | $10.10B |
| Operating Margin | 22.10% |
| Return on Equity | 9.84% |
| Return on Assets | 4.92% |
| Revenue/Share (TTM) | $28.37 |
| Book Value | $38.64 |
| Price-to-Book | 2.15 |
| Price-to-Sales (TTM) | 2.89 |
| EV/Revenue | 3.444 |
| EV/EBITDA | 12.77 |
| Quarterly Earnings Growth (YoY) | 18.30% |
| Quarterly Revenue Growth (YoY) | 9.90% |
| Shares Outstanding | $1.28B |
| Float | $1.28B |
| % Insiders | 0.31% |
| % Institutions | 89.63% |
Volatility is currently expanding
Medtronic is a dividend aristocrat with a near-decade high yield, making it an attractive long-term income opportunity. The company is experiencing strong revenue growth, driven by its leading positions in cardiovascular and neuroscience medical devices. While current free cash flow payout ratios are sustainable, investors should monitor future dividend growth rates closely.
Medtronic (MDT) reported earnings 30 days ago. What's next for the stock?
Globus Medical or Medtronic? See why Globus Medical's stronger growth, innovation and analyst upside may give it the edge despite a richer valuation.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Medtronic offers high growth potential in addition to discounted valuation.
Investors need to pay close attention to MDT stock based on the movements in the options market lately.
Acquisition delivers simplicity and access, supporting physicians across the full procedural workflow GALWAY, Ireland, June 12, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it has completed its acquisition of Scientia Vascular, a privately-held medical device company in Salt Lake City. The acquisition is valued at $550 million, subject to customary adjustments, with potential undisclosed earn-out and milestone payments post-acquisition.
MDT is betting on ablation, robotics and hypertension therapies as next growth drivers, but tariffs, FX and pricing pressures cloud near-term upside.
MDT trades at about 14x forward earnings with a 3.5% yield as fiscal 2027 guidance points to steady growth, but margins face tariffs and mix pressure.
Medtronic's growth rate in its most recent fiscal year was the highest it's achieved in a decade. Its stock is undervalued, and it also pays a high dividend.
